Company intelligence / Profile preview
N-Zyme Biomedical
United Statesnzymebio.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
N-Zyme Biomedical has developed a novel class of pepsin inhibitor therapies targeting LPR and GERD. Their lead program, NZYM-001, uses a repurposed HIV protease inhibitor formulated as an oral suspension and dry powder inhaler to locally inhibit pepsin activity. The company’s approach leverages existing safety data to accelerate clinical development. A Phase II proof-of-concept trial for their proprietary sustained-release oral fosamprenavir sodium alginate formulation will begin enrollment in Spring 2025. An IND has been approved by the FDA for a related study at the Medical College of Wisconsin using standard fosamprenavir/Lexiva.
- Therapeutic areas
- Gastroenterology
- Modalities
- Repurposed small molecule drugs (notably HIV protease inhibitors such as fosamprenavir)Oral suspension formulationsDry powder inhaler formulations
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
LGM Pharma – CDMO partner supporting API sourcing, drug product manufacturing, and clinical supply chain management for new prolonged release formulations.Medical College of Wisconsin – Clinical research collaboration on IND-approved trials.
Beyond the preview
Go deeper on N-Zyme Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-Zyme Biomedical.